Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.57 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.56 |
| ▸ | SCN2B | O60939 | 1/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.56 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.56 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984819 | 0.83 | HDAC8 (0.64) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2159159 | 0.82 | PKM (0.51) | HDAC8HDAC6MEN1KMT2ASCN9A | |
| SCHEMBL13331743 | 0.82 | KDM4E (0.65) | HDAC8HDAC6MEN1KMT2ASCN9A | |
| SCHEMBL20118983 | 0.81 | HDAC8 (0.62) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15695582 | 0.81 | SCN9A (0.47) | HDAC8HDAC6SCN9ASCN2BSCN1A | |
| SCHEMBL30929655 | 0.81 | HDAC6 (1.00) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5242529 | 0.81 | HDAC6 (1.00) | HDAC8HDAC6SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22097515 | 0.81 | HDAC1 (0.50) | HDAC8HDAC6SMN1; SMN2SCN9ASCN2B | |
| SCHEMBL7990892 | 0.81 | HDAC1 (0.66) | HDAC6MEN1KMT2AKCNK3KCNK9 | |
| SCHEMBL3348416 | 0.81 | FLT1 (0.60) | SMN1; SMN2MEN1KMT2AKAT6APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400503-A2 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-113773275-B | Antiviral compound and preparation method thereof | 广东中科药物研究有限公司 | 2023-04-25 | — | — | CN | disclosed |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | PHENEX PHARMACEUTICALS AG (DE) | 2019-05-16 | — | — | US | disclosed |
| EP-3233831-B1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018081285-A1 | UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-9938278-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-3246070-A1 | NOVEL FXR (NR1H4) BINDING AND ACTIVITY MODULATING AZOLES | Gilead Sciences, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9820979-B2 | FXR (NR1H4) binding and activity modulating compounds | GILEAD SCIENCES, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170298068-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| WO-2011043359-A1 | PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND | 協和発酵キリン株式会社 (JP) | 2011-04-14 | — | — | WO | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-6331628-B1 | REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298068-A1 | NOVEL FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | HDAC8 365/4885HDAC6 276/4885SMN1; SMN2 4797/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | HDAC8 1671/4885HDAC6 2255/4885SMN1; SMN2 1437/4885 |
| US-20190142814-A1 | Novel FXR (NR1H4) binding and activity modulating compounds | NR1H4, NR1H2, NR1H3 | HDAC8 258/4885HDAC6 219/4885SMN1; SMN2 4827/4885 |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | HDAC8 4431/4885HDAC6 3054/4885SMN1; SMN2 2111/4885 |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | CYSLTR2, PTGER2, CYSLTR1 | HDAC8 4431/4885HDAC6 3054/4885SMN1; SMN2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.